Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia

Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Zhixiang Shen, Guoqiang Chen, Jian-Hua Ni et al. · Blood · 1997 · 1.4K citations

Medicine, Pharmacokinetics, Pharmacology +17

Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia

Ari Melnick, Jonathan D. Licht · Blood · 1999 · 1K citations

Medicine, Molecular Biology, Oncology +12

United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia

Steven L. Soignet, Stanley R. Frankel, Dan Douer et al. · Journal of Clinical Oncology · 2001 · 825 citations

Medicine, Hematology, Oncology +15

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Guoqiang Chen, Xuegeng Shi, Wei Tang et al. · PubMed · 1997 · 803 citations

Medicine, Hematology, Oncology +14

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

Stanley R. Frankel, Gregory Y. Lauwers, Mark A. Weiss et al. · Annals of Internal Medicine · 1992 · 716 citations · Full text

Medicine, Hematology, Oncology +11